Older ablation approaches for ventricular tachycardia have been suboptimal, Medtronic said. The company plans to bring a more effective treatment for the life-threatening heart condition.
In science, the suffix “phage” means to devour. Thus, the name bacteriophage might conjure images of tiny creatures that “eat” bacteria. While that conception isn’t 100% scientifically accurate, bacteriophages are lethal killers of bacteria nonetheless, and scientists are excited about engineering phage DNA as a path to new antibiotics.
The system pairs a 122‑electrode spherical array with real‑time thermal contact sensing and visualisation to guide ablation and confirm treatment.
The inconspicuous nucleocapsid protein from coronaviruses can trigger hyperinflammation, an effect not typically seen in other viruses.
A new open resource of cancer models has enabled researchers to create the first large-scale map of the genes that cancers rely on to survive, offering new avenues for research into better and less toxic treatments for patients.
Researchers from the Rolf Luft Research Center for Diabetes and Endocrinology at Karolinska Institutet have developed a targeted RNA technology to prepare pancreatic islet cells for transplantation.
Some 33 million Americans have severe food allergies. Now, researchers at Boston Children’s Hospital may have found a promising solution.
Mayo Clinic researchers have developed an experimental drug with the help of artificial intelligence (AI) to target the “undruggable” PDZ domain of the GIPC1 protein, which helps different types of cancer, including pancreatic cancer, grow and resist treatment. In laboratory studies, the drug slowed tumor growth, improved survival and enhanced the effects of the chemotherapy drug gemcitabine.
Researchers at Baylor College of Medicine have developed a drug called CS18 that disrupts cancer cells’ ability to survive therapy. The findings, published in Science Advances, support exploring the possibility of using CS18 to treat human cancer in the future.
BURLINGTON, N.C., Aug. 4, 2026 /PRNewswire/ — Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced the nationwide availability of Roche’s VENTANA® PTEN (SP218) RxDx Assay, the first immunohistochemistry (IHC) companion diagnostic test approved by the U.S. Food and Drug Administration (FDA) to determine PTEN protein loss, also known as PTEN deficiency, in tumors of patients with prostate adenocarcinoma. The assay helps identify patients who may be eligible for treatment with AstraZeneca’s TRUQAP® (capivasertib) in combination with abiraterone acetate and prednisone.